Capecitabine monotherapy: Review of studies in first-line HER-2-negative metastatic breast cancer

Oncologist

Volumn 17, Issue 4, 2012, Pages 476-484

  O'Shaughnessy, Joyce A ^a   Kaufmann, Manfred ^b   Siedentopf, Friederike ^c   Dalivoust, Philippe ^d   Debled, Marc ^e   Robert, Nicholas J ^f   Harbeck, Nadia ^g  

^a TEXAS ONCOLOGY   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Praxis für Gynäkologie Dr Schoenegg   (Germany)

^d Hospital Ambroise Pare   (France)

^e INSTITUT BERGONIÉ   (France)

^f Virginia Cancer Specialists   (United States)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Capecitabine; Chemotherapy; First line therapy; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IXABEPILONE; LAPATINIB; METHOTREXATE; NAVELBINE; PLACEBO; SORAFENIB; TAXANE DERIVATIVE; TRASTUZUMAB; UROKINASE;

ALOPECIA; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; BREAST CANCER; BREAST METASTASIS; CANCER RELAPSE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEART DISEASE; HEART INFARCTION; HUMAN; LEUKOPENIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; REVIEW; STOMATITIS; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 84860170213     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0281     Document Type: Review

References (48)

1. Beslija S, Bonneterre J, Burstein H et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007;18:215-225.
2. Gelmon K, Chan A, Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. The Oncologist 2006; 11(suppl 1):42-51.
3. Debled M, Madranges N, Trainaud A et al. Firstline capecitabine monotherapy for slowly progressing metastatic breast cancer: Do we need aggressive treatment? Oncology 2009;77:318-327.
4. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
5. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-4174.
6. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352:930-942.
7. De Laurentiis M, Cancello G, D'Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53.
8. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: Highlights of the St Gallen international Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-1329.
9. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Breast Cancer Screening and Diagnosis, v. 1.2010. Available at http://demystifyingmedicine.od.nih.gov/DM10/0413-BreastCancer/NCCN%20breastscreening.pdf, Accessed 5 July, 2011.
10. Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). AGOGuidelines. Available at http://www.agoonline.de/_download/unprotected/g_mamma_11_1_0_20_cytotoxic_therapy_metastatic_bc.pdf Updated March 2011, accessed July, 2011.
11. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
12. Leonard R, Hennessy BT, Blum JL et al. Doseadjusting capecitabine minimizes side effects while maintaining efficacy: A retrospective review of capecitabine for metastatic breast cancer. Clin Breast Cancer 2011;11:349-356.
13. Górnaś M, Szczylik C. Oral treatment of metastatic breast cancer with capecitabine: What influences the decision-making process? Eur J Cancer Care 2010;19:131-136.
14. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
15. Cameron D, Casey M, Press M et al. Aphase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-543.
16. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009; 27:1999-2006.
17. Stockler MR, Harvey VJ, Francis PA et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011;29:4498-4504.
18. Jäger E, Al-Batran S, Saupe S et al. A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study. J Clin Oncol 2010;28(15 suppl):1022.
19. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29: 1252-1260.
20. Vahdat L, Fein LE, Karwal MW et al. Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: A pooled analysis from two phase III studies. Cancer Res 2009;69(suppl 2):6117.
21. Kaufmann M, Maass N, Costa SD et al. Firstline therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial. Eur J Cancer 2010;46:3184-3191.
22. Baselga J, Segalla JGM, Roché H et al. SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic breast cancer [abstract 3]. Eur J Cancer Suppl 2009;7: 3LBA.
23. Baselga JB, Roché H, Costa F et al. SOLTI-0701: A multinational, double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo in combination with capecitabine in patients with locally advanced or metastatic breast cancer. Cancer Res 2009;69(suppl 3):45.
24. O'Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/ metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
25. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002;49:211-216.
26. Higgins B, Kolinsky K, Linn M et al. Antitumour activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. Anticancer Res 2007;27:2279-2288.
27. Goldstein LJ, Stemmer SM, Schmalfeldt B et al. Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2010;28(15 suppl):TPS131.
28. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracyclines and taxane treatment. J Clin Oncol 2007;25:5210-5217.
29. Hortobagyi GN, Gomez HL, Li RK et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2010;122:409-418.
30. Hortobagyi GN, Perez E, Vrdoljak E et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either Ixabepilone (I) plus capecitabine I or C alone: Results from two randomized phase III trials [abstract 186]. Presented at the 2008 Breast Cancer Symposium-Integrating Emerging Science Into Clinical Practice, Washington, DC, September 5-7 2008.
31. Siedentopf F, Gohler T, Hesse T et al. Capecitabine in the routine treatment of advanced breast cancer: Results from a non-interventional observational study in 876 patients. Onkologie 2009;32: 631-636.
32. Dalivoust P, Debled M, Asselain B et al. Capecitabine therapy for locally advanced or metastatic breast cancer: A difference between reported clinical trials and routine clinical practice? Results from the ELIXIR study in routine oncology practice. Cancer Res 2010;70(suppl 24):P6-11-04.
33. Debled M, Madranges N, Mertens C et al. Firstline chemotherapy for metastatic breast cancer in patients ≥75 years: A retrospective single-centre analysis. Crit Rev Oncol Hematol 2011;80:171-179.
34. Feher O, Vodvarka P, Jassem J et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: A multicenter, randomized, phase III study. Ann Oncol 2005;16:899-908.
35. Roché H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25: 3415-3420.
36. Fumoleau P, Delgado FM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-1252.
37. Bruno S, Puerto VL, Mickiewicz E et al. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 1995; 18:392-396.
38. Mulders M, Vingerhoets A, Breed W. The impact of cancer and chemotherapy: Perceptual similarities and differences between cancer patients, nurses and physicians. Eur J Oncol Nurs 2008;12: 97-102.
39. Lemieux J, Maunsell E, Provencher L. Chemotherapy- induced alopecia and effects on quality of life among women with breast cancer: A literature review. Psychooncology 2008;17:317-328.
40. Gajria D, Feigin K, Tan LK et al. Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer 2011;117:4125-4131.
41. Gajria D, Gonzalez J, Feigin K et al. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2012;131:111-116.
42. Kusama M, Nomizu T, Aogi K et al. Phase II study of 4-weekly capecitabine monotherapy in advanced/ metastatic breast cancer. Breast Cancer 2010;17:233-240.
43. Taguchi T, Nakayama T, Masuda N et al. Study of low-dose capecitabine for metastatic breast cancer. Chemotherapy 2010;56:166-170.
44. Martín M, Marténez N, Ramos M et al. Randomized, phase II trial comparing continuous vs intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009-05 study. J Clin Oncol 2011;29(15 suppl):1008.
45. Gilabert M, Bertucci F, Esterni B et al. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: Response, survival and prognostic factors. Anticancer Res 2011;31:1079-1086.
46. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: An open-label, randomised controlled trial. Lancet Oncol 2009;10:1145-1151.
47. O'Shaughnessy J, Paul D, Stokoe C et al. First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide followed by docetaxel with or without capecitabine in high-risk early breast cancer. Cancer Res 2010;70(suppl 24):S4-2.
48. Verma S, Zielinski C, Martín M. Evolution of chemotherapy options in HER2-negative metastatic breast cancer (MBC). Ann Oncol 2010;21(8 suppl): Abstract 282PD.